Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4934882 | Schizophrenia Research | 2017 | 7 Pages |
Abstract
Antipsychotic Induced Weight Gain (AIWG) is a common and severe side effect of many antipsychotic medications. Mitochondria play a vital role for whole-body energy homeostasis and there is increasing evidence that antipsychotics modulate mitochondrial function. This study aimed to examine the role of variants in nuclear-encoded mitochondrial genes and the mitochondrial DNA (mtDNA) in conferring risk for AIWG. We selected 168 European-Caucasian individuals from the CATIE sample based upon meeting criteria of multiple weight measures while taking selected antipsychotics (risperidone, quetiapine or olanzapine). We tested the association of 670 nuclear-encoded mitochondrial genes with weight change (%) using MAGMA software. Thirty of these genes showed nominally significant P-values (<Â 0.05). We were able to replicate the association of three genes, CLPB, PARL, and ACAD10, with weight change (%) in an independent prospectively assessed AIWG sample. We analyzed mtDNA variants in a subset of 74 of these individuals using next-generation sequencing. No common or rare mtDNA variants were found to be significantly associated with weight change (%) in our sample. Additionally, analysis of mitochondrial haplogroups showed no association with weight change (%). In conclusion, our findings suggest nuclear-encoded mitochondrial genes play a role in AIWG. Replication in larger sample is required to validate our initial report of mtDNA variants in AIWG.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Kirti Mittal, Vanessa F. Gonçalves, Ricardo Harripaul, Ari B. Cuperfain, Brandi Rollins, Arun K. Tiwari, Clement C. Zai, Malgorzata Maciukiewicz, Daniel J. Müller, Marquis P. Vawter, James L. Kennedy,